Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2017

View Archived Issues

Generon initiates phase I trial of A-337 in Australia

Combined stem cell-virotherapy reduces experimental ovarian cancer

Aequus files Canadian CTA for anti-nausea patch AQS-1303

[18F]JHU-16907, a novel PET probe targeting Mer tyrosine kinase

HbA1c reductions seen with Roche's GIP/GLP-1 receptor agonist NNC-0090-2746 in type 2 diabetes

Peloton partners with University of Texas on ubiquitin ligase research for cancer

RedHill reports phase III results on Bekinda for acute gastroenteritis and gastritis

Q BioMed enters license agreement for uttrocide B for liver cancer

GVK Biosciences patents PI3Kbeta inhibitors

Taiho Pharmaceutical discloses androgen receptor antagonists

Arnuity Ellipta launched in Japan

Mitsubishi Tanabe Pharma discovers MC1 receptor agonists

Lieber Institute for Brain Development divulges COMT inhibitors

R-Pharm CJSC patent describes dual ALK and EGFR inhibitors

Human Longevity and Merck KGaA establish cancer biomarker agreement

Sirnaomics reports findings on STP-705 for liver fibrosis

Johnson & Johnson Innovation announces new collaborations

First-in-human data for MVT-2163 PET imaging in CA 19-9-positive malignancies

Johnson & Johnson completes Actelion acquisition

FDA grants orphan drug designation to ResQ's LipidRescue

Immune Pharmaceuticals to regain worldwide rights to Ceplene

Discovery and in vivo evaluation of two PET radioligands of muscarinic acetylcholine M1 receptor

Ionis initiates phase I/II study of IONIS-MAPTRx in mild Alzheimer's disease

NICE recommends olaratumab in combination with doxorubicin for the treatment of soft tissue sarcoma

Launch of NGN-PET project to explore and model neuron-glial networks in neuropathic pain

Arginase inhibitor CB-1158 well tolerated in first-in-human study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...